Vaqar Ali, MD
Interventional Cardiology · Jacksonville, FLNPI 1154379048
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,458 of the $30,225 with a category attached, or 64.4%. 58 manufacturers reported payments, led by Abbott at 30.5% of the total. 2025 is the largest year on record at $7,720, 4.2 times the $1,823 reported in 2019.
Across 541 payments — averaging $55.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Endologix LLC$3K
- Bard Peripheral Vascular, Inc.$3K
- Edwards Lifesciences$2K
- Abiomed$1K
- Medtronic$1K
- plus $10K from 52 others
Across 87 payments — averaging $2356.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$61K
- Endologix LLC$50K
- M.a. Med Alliance S.A.$47K
- Intact Vascular, Inc.$14K
- Medalliance LLC$13K
- Bard Peripheral Vascular, Inc.$10K
- plus $10K from 2 others
What the payments were for
- Consulting fees$6,55022%
- Speaking & faculty fees$1,6505%
- Travel & lodging$2,5198%
- Food & beverage$19,45864%
- Education$480%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACCULINK$4,000
- XACT$3,001
- ENDOCROSS Device$2,422
- Torus Stent Graft System$2,422
- Impella$969
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$408
- Repatha$337
- Edwards SAPIEN 3 Transcatheter Heart Valve$311
- MitraClip System$289
- Venclose Maven Catheter$278
- CoreValve Evolut$266
- SAPIEN 3 Ultra RESILIA$261
- GENERAL - STENTS$251
- Alto Abdominal Stent Graft System$239
- MitraClip$228
- OptoWire$218
- OptoMonitor$218
- Edwards SAPIEN XT Transcatheter Heart Valve$181
- ESPRIT$163
- Optis Coronary Imaging System$157
How this compares
$30,225 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $228,306 |
| CamzyosMavacamten | 13 | $93,337 |
| XareltoRivaroxaban | 70 | $92,384 |
| JardianceEmpagliflozin | 79 | $90,578 |
| EntrestoSacubitril/Valsartan | 65 | $86,647 |
| FarxigaDapagliflozin Propanediol | 31 | $42,562 |
| Repatha SureclickEvolocumab | 50 | $41,972 |
| Repatha SyringeEvolocumab | 26 | $23,420 |
| OzempicSemaglutide | 12 | $11,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,532 |
| Ranolazine ErRanolazine | 41 | $6,844 |
| Prasugrel Hcl | 34 | $6,187 |
| ClopidogrelClopidogrel Bisulfate | 381 | $3,478 |
| Metoprolol Succinate | 270 | $3,066 |
| Atorvastatin Calcium | 372 | $2,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $251 | $228,306184 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $335 | $93,33713 claims |
| Johnson & JohnsonXarelto | $164 | $92,38470 claims |
| Boehringer IngelheimJardiance | $282 | $90,57879 claims |
| NovartisEntresto | $492 | $86,64765 claims |
| AstraZenecaFarxiga | $412 | $42,56231 claims |
| Novo NordiskOzempic | $24 | $11,62212 claims |
| GSKTrelegy Ellipta | $12 | $10,53211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Jacksonville
- Siddharth WayangankarJacksonville$1.2M
- Dominick AngiolilloJacksonville$387K
- Ruby SatpathyJacksonville$205K
- Bharat GummadiJacksonville$153K
- Raguveer MurthyJacksonville$65K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.